Frank Herting
CS Diagnostics(DE)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Angiogenesis and VEGF in Cancer, Glycosylation and Glycoproteins Research, Peptidase Inhibition and Analysis, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models(2013)353 cited
- → Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy(2013)197 cited
- → RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis(2016)131 cited
- → Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101(2011)127 cited
- → Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy(2019)86 cited
- → Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo(2016)80 cited
- → A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors(2013)67 cited
- → Primary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs(2010)62 cited
- → Characterization of a re‐engineered, mesothelin‐targetedPseudomonasexotoxin fusion protein for lung cancer therapy(2016)56 cited
- → Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma(2013)49 cited